중국의 ‘알츠하이머 치매 수술’ 논란…기적의 치료법인가, 일시적 착시인가

A recent Chinese surgical procedure targeting Alzheimer's disease has sparked controversy and debate. Known as 'DCLLVA' or 'deep cervical lymphatic-venous anastomosis,' the surgery aims to alleviate the condition by removing toxic proteins from the brain. The technique involves connecting lymphatic vessels in the neck to nearby arteries, allowing toxic proteins to bypass the brain and exit the body.

This approach was first used in 2020 on an 80-year-old Alzheimer's patient, with reportedly positive results. However, the procedure has not been widely adopted due to a lack of scientific evidence and concerns over safety and ethics. Despite this, some Chinese hospitals have continued to perform the surgery, while foreign nations have initiated smaller clinical trials.

Experts remain divided on the effectiveness and long-term implications of this experimental treatment.